1. Clinical prognostic value of different NPM1 mutations in acute myeloid leukemia patients.
- Author
-
Shi, Yu, Chen, Xiao, Jin, Huimin, Zhu, Liying, Hong, Ming, Zhu, Yu, Wu, Yujie, Qiu, Hairong, Wang, Yan, Sun, Qian, Jin, Hui, Li, Jianyong, Qian, Sixuan, and Qiao, Chun
- Subjects
ACUTE myeloid leukemia ,PROGNOSIS ,MOLECULAR biology ,OVERALL survival ,GENETIC mutation ,PRELEUKEMIA - Abstract
Background: Acute myeloid leukemia (AML) patients with various nucleophosmin 1 (NPM1) mutations are controversial in the prognosis. This study aimed to investigate the prognosis of patients according to types of NPM1 mutations (NPM1
mut ). Methods: Bone marrow samples of 528 patients newly diagnosed with AML, were collected for morphology, immunology, cytogenetics, and molecular biology examinations. Gene mutations were detected by next-generation sequencing (NGS) technology. Results: About 25.2% of cases exhibited NPM1mut . 83.5% of cases were type A, while type B and D were respectively account for 2.3% and 3.0%. Furthermore, 15 cases of rare types were identified, of which 2 cases have not been reported. Clinical characteristics were similar between patients with A-type NPM1 mutations (NPM1A − type mut ) and non-A-type NPM1 mutations (NPM1non − A−type mut ). Event-free survival (EFS) was significantly different between patients with low NPM1non − A−type mut variant allele frequency (VAF) and low NPM1A − type mut VAF (median EFS = 3.9 vs. 8.5 months, P = 0.020). The median overall survival (OS) of the NPM1non − A−type mut FLT3-ITDmut group, the NPM1A − type mut FLT3-ITDmut group, the NPM1non − A−type mut FLT3-ITDwt group, and the NPM1A − type mut FLT3-ITDwt group were 3.9, 10.7, 17.3 and 18.8 months, while the median EFS of the corresponding groups was 1.4, 5.0, 7.6 and 9.2 months (P < 0.0001 and P = 0.004, respectively). Conclusions: No significant difference was observed in OS and EFS between patients with NPM1A − type mut and NPM1non − A−type mut . However, types of NPM1 mutations and the status of FLT3-ITD mutations may jointly have an impact on the prognosis of AML patients. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF